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Abstract
Background: The purpose of this work was to explore the knowledge and acceptance of Varicella Zoster Virus (VZV)-
Herpes Zoster (HZ) vaccination in the general Italian population, where the HZ vaccine has not yet been distributed, 
using a prevalence study of subjects from two regions in Italy.
Methods: A group of 3,173 individuals were interviewed using a questionnaire. The youngest age group (≤ 20 year) 
was composed of students interviewed at university. The middle age group (21-40 years) and the older age group (≥ 
41 years) were interviewed by general practitioners in their office.
Results: In both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects 
reported receiving the VZV vaccination. Regarding HZ, 2,749 (86.6%) individuals stated that they knew of the virus and 
2,233 (70%) were willing to be vaccinated against HZ. The majority of people willing to be vaccinated were in the 
middle and older age groups (36.6% and 44.7%, respectively).
Conclusion: Compliance versus vaccination results were satisfactory and probably, with the upcoming availability of 
the HZ vaccine in Italy, adults will be favourably disposed towards vaccination.
Background
Worldwide, varicella-zoster virus (VZV) infection (chick-
enpox) affects millions of individuals, causing significant
suffering. During primary infection, the virus migrates to
the dorsal root and cranial root ganglia, where it remains
latent. Herpes zoster (HZ, shingles) is the result of reacti-
vation of dormant VZV in the ganglia [1]. HZ causes
acute and chronic morbidity and is characterized by a
painful vesicular unilateral dermatomal rash. The most
common HZ complication is post-herpetic neuralgia
(PHN), which consists of burning pain, paresthesias, dys-
esthesia, pruritus, or anesthesia in the affected area and
most frequently develops in subjects over 60 years of age.
The risk of developing HZ in people exposed to VZV
ranges from 10% to 30%, with an increased incidence in
older individuals and in immunocompromised hosts [2-
6]. Cell-mediate immunity (CMI) is thought to be impor-
tant in defense against VZV infection. Therefore, a defec-
tive CMI is a major factor in virus reactivation [1].
It has been predicted that a quarter of the general pop-
ulation will be affected by HZV reactivation during their
lifetime [7]. In the United States (US), an estimated one
million cases of HZ infection occur each year, with an
incidence of 11.12 cases per 1,000 patient-years and there
are higher incidence rates and number of hospitalizations
among older adults (> 50 years) [8-12]. Studies examining
the general population of European countries demon-
strated that the incidence of HZ in all ages ranges was
from 1.2 to 4.8 cases per 1000 person-years and, among
people > 60 years of age, it was 7.2 to 11.8 cases per 1,000
person-years [13,14]. Also, in a Spanish study, the major-
ity of hospitalizations for HZ occurred in adults over 50
years of age [15]. In Italy, a regional survey conducted in
2007 reported a total incidence of 1.74 HZ cases/1000
population per year, over a period of 14 years and an inci-
dence of hospital admissions of 0.12/1000 inhabitants,
with an average cost of €4082.59 per hospitalization [16].
In 2006, an HZ vaccine was approved by the US Food
and Drug Administration (US FDA) and recommended
by the Advisory Committee on Immunization Practices
(ACIP) for the prevention of shingles in individuals ≥ 60
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years old. In the same year, European Medicines Agency
(EMEA) gave its Marketing Authorization valid through-
out the European Union to this product. EU approval
states that the recommended age of vaccination starts
from 50 yrs of age instead of 60 yrs of age as in the USA
http://www.ema.europa.eu/humandocs/Humans/EPAR/
zostavax/zostavax.htm. This new vaccine is made of the
same live attenuated VZV strain used in the varicella vac-
cine, but it has a potency at least 14-times higher than
that of single-antigen varicella vaccine, which is necessary
to confer protection against zoster [17]. It boosts the CMI
against HZ, thus reducing the incidence of the disease
and severity [8,18-20]. Efficacy, safety and tolerability of a
high titre VZV vaccine for the prevention of HZ infection
and its sequelae were demonstrated in a multicentric
study of over 38,000 older adults [9,10].
Nowadays, the vaccine is only distributed in USA; vac-
cination has been recommended in Austria and Switzer-
land and it should be soon included in European geriatric
guidelines [21].
In Italy, the HZ vaccine is not yet commercially avail-
able, though, it is about to be distributed. However, few
population-based studies have been performed in Italy
assessing the subjective perception of the relevance of
VZV to health and the importance of vaccination. The
aim of this study was to explore the knowledge of VZV
infections in the general population of two Italian regions
and analyze the VZV vaccine immunization status and
the acceptance of HZ vaccination.
Methods
The sample group was composed by 3,173 subjects from
two Italian Regions, Campania and Lazio. Subjects were
consecutively enrolled: the youngest age group (≤ 20
year) was composed of university students interviewed by
teachers; the middle age group (21-40 years) and the
eldest age group (≥ 41 years) were interviewed by general
practitioners in their office. Face-to-face interviews were
done by administrating a brief questionnaire divided in
two sections (Additional file 1).
The first section included general questions about sex,
age, level of education, residence and nationality. In the
second section, the subjects were asked about their
knowledge of and personal experience with both chicken-
pox and shingles, and also, about their compliance versus
HZ vaccination. Questionnaire was developed on the
basis of previous experiences in collaboration with Sanofi
Pasteur MSD and tested on a sample of university stu-
dents. Statistical analysis was performed using the Epi
Info software, version 3.32.
Results
Of the 3,173 subjects interviewed, 1,469 (46.3%) were
men. The median age for both men and women was 36
years, ranging from 16 to 92 years. Overall, 2,017 subjects
(63.5%) reported higher educational levels, i.e., secondary
school and university. Moreover, the sample was homo-
geneously distributed within the two regions (Table 1). In
the population interviewed, 2,256 (71.1%) individuals
claimed that they had had chickenpox during their life-
time (22%, 41.4% and 36.7% from the three age groups,
respectively). Only 165 individuals (5.2%) reported being
vaccinated for VZV. With regard to the knowledge of HZ,
2,749 individuals (86.6%) reported that they knew of the
disease and, notably, 352 (11.1%) had had the disease in
the past (Table 2). Of the 2,082 individuals who reported
that they knew the severity of the disease, 1,528 subjects
were 1.5 times more probable to accept the vaccination
(OR 1.5, CI.95 = 1.29-1.77, p-value = 1 × 10-6). Comparing
financial statements, and using the educational level as a
surrogate, people with higher educational levels (degree
and secondary school) seem to be more likely to accept
vaccination than those with a lower educational level
Table 1: Characteristics of subjects interviewed
N. %
Area of residence:
Lazio 1,456 45.8
Campania 1,717 54.1
Sex:
Females 1,704 53.7
Males 1,469 46.3
Age:
<21 594 18.7
21-40 1,162 36.6
≥41 1,417 44.7
Nationality:
Other 89 2.8
Italian 3,084 97.2
Education:
None 152 4.8
Primary/Middle school 1,004 31.6
Secondary school 1,724 54.3
University 293 9.2Parlato et al. BMC Public Health 2010, 10:333
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(primary school) (OR 0.65, CI.95 = 0.48-0.89, p-value < .05
compared to OR 0.63, CI.95 = 0.90, p-value < .05, respec-
tively). Moreover, individuals who have had VZV in the
past are more likely to accept the vaccination than people
with no previous history of VZV (OR 1.3, CI.95 = 1.10-
1.54, p-value = .001).
Among the 3,173 individuals interviewed about their
knowledge of HZ, with respect to the acceptance of the
vaccination, 1,960 (61.77%) individuals claimed to be
amenable towards this type of prevention because they
were familiar with the disease (OR 1.4, CI.95 = 1.17-1.82,
p-value = 7 × 10-4). Furthermore, there were more people
who were willing to be vaccinated in the middle and older
adult age groups (36.6% and 44.7%, respectively) than in
the youngest age class (OR 1.34, CI.95 = 1.07-1.66, p-value
= 7 × 10-3).
Discussion
VZV can cause two clinical conditions, the first results
from the primary infection and the second is due to reac-
tivation of the virus following the initial infection. Both of
these diseases are often associated with severe complica-
tions. In 1995, a varicella vaccination program was imple-
mented in the United States [22]. The immediate goal of
the extensive vaccination against VZV was to signifi-
cantly decrease the morbidity and mortality associated
with the disease. With widespread vaccination, there has
been a concomitant decline in the incidence of the dis-
ease, along with a decrease in hospitalizations and deaths
due to VZV infection [23]. To improve protection, a two-
dose schedule of immunization was recommended for
routine use in children by the Centers for Disease Control
and Prevention (CDCs) in June 2006. At the same time,
the licensure of the combined measles-mumps-rubella-
varicella vaccine was completed, which allowed harmoni-
zation of immunization against these four viruses with
one injection given twice in childhood [23,24].
The Shingles Prevention Study, a case-control study
examining the widespread immunization against VZV,
established that the zoster vaccine was safe, well-toler-
ated, and effective at reducing the burden of illness due to
HZ and the incidence of PHN [9,10,25-27].
In 2006, the US FDA licensed the HZ vaccine [8], which
promises to reduce the morbidity and mortality of HZ. In
fact, administration of the vaccine to younger people may
offer a good cost-benefit balance [28].
The availability of a specific anti-zoster vaccine could
offer an important tool for reducing health problems and
improve the overall quality of life in the elderly, as dem-
onstrated by several studies [29-32]. A combined immu-
nization against both varicella in childhood and HZ in
adulthood in the developed world could improve the con-
trol of the virus [23]. The future challenge is represented
by the prediction of how the decrease in VZV circulation
will affect immunity among both vaccinated and unvacci-
nated individuals: varicella will continue to occur even in
a highly immunized population, because of the ability of
VZV to reactivate as zoster. Studies have predicted that
there will be an increase in HZ incidence until the adult
population becomes predominantly composed of individ-
uals with vaccine-induced immunity who do not harbour
wild-type VZV [22]. Moreover, VZV vaccination in chil-
dren, without optimal coverage, can shift the disease to
adults, leading to severe illness and a higher incidence of
herpes zoster. Vaccination strategies will likely need to be
adjusted as the epidemiology of VZV and risk factors
continues to evolve [33]. Some risk factors may help to
redirect preventive vaccination strategies. Hicks et al.
demonstrated that, in a cohort of non-immunocompro-
mised subjects, there was a strong association between
the development of HZ and a family history of HZ, sug-
gesting that these individuals were at high risk for HZ
infection. These individuals could be the primary target
for vaccination, thus, decreasing both their possibility of
VZV infection and health care expenditures due to HZ
morbidity [34].
Age can also be considered as a risk factor: active HZV
vaccination of individuals > 50 years of age, simultane-
ously or in sequence with anti-influenza vaccination, has
been demonstrated to be an effective, well-tolerated
strategy [35,36]. Few studies have been conducted to
investigate the social and epidemiological problems
related to shingles disease or to the spread of immuniza-
tion. In a recent global survey about awareness, knowl-
Table 2: Individuals who know or who were affected by VZV-associated diseases and their compliance with vaccinations
Varicella HZ
subjects
(n. 3173)
knowing (n. 
3071)
affected (n. 
2256)
immunized (n. 165) knowing (n. 
2749)
affected (n. 
352)
compliance (n. 
2233)
young N = 594 35.1% 22.0% 64.4% 28.4% 3.04% 18.7%
adults N = 1,162 33.5% 41.4% 28.5% 34.0% 41.2% 36.6%
older N = 1,417 31.4% 36.7% 9.09% 37.6% 55.7% 44.7%Parlato et al. BMC Public Health 2010, 10:333
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edge, symptoms and treatment of HZ among 8,688 adults
≥ 50 years of age in 22 countries, there was wide variation
in HZ awareness among the different areas and, almost,
universally poor knowledge of the causes and symptoms
of HZ were reported. Moreover, the majority of respon-
dents were unaware of their risk of HZ. This survey sug-
gests a population-wide effort to improve global
awareness of HZ would be required for a successful vac-
cine initiative [37].
In the Netherlands, Opstelten et al. evaluated the deter-
minants of non-compliance with HZ vaccination in com-
munity-dwelling elderly to whom a free HZ vaccination
was offered simultaneously with the yearly influenza vac-
cination. In all, 690 patients (39%) were vaccinated
against HZ, while 1,349 patients (76%) accepted influenza
vaccination. Determinants of non-compliance with HZ
vaccination included the perceived lack of recommenda-
tion by the GP, unwillingness to comply with the doctor's
advice, perception of low risk for contracting HZ, percep-
tion of a short pain duration for HZ and the opinion that
vaccinations weaken natural immunity [38].
In the present study we have compared attitude, knowl-
edge and experience about VZV-associated diseases of
individuals from different age groups in two different
regions in Italy. In both regions, the majority of subjects
had been affected by varicella infection, while a low per-
centage (5%) had been vaccinated against VZV. Regarding
perception and availability of the HZ vaccination, in both
regions, adults over the age of 21 seemed to be willing to
accept this vaccination. This is probably due to greater
knowledge of the infection/disease in this population and
to a direct, or indirect, experience with HZ in the older
age group.
Finally, limits and biases of this study should be men-
tioned. A cross-sectional study measures the prevalence
of an outcome of interest in a certain population at a cer-
tain time point or over a short period. We have explored
the acceptability of the HZ vaccination in people using
face to face interviews, carried out by their pratictioners
and in university staff. We randomly selected the inter-
viewed population in two Italian regions, Lazio and Cam-
pania. Indeed, each of the associations identified in the
current study must be interpreted with caution because
our sample is not representative of the entire Italian pop-
ulation and study inclusion or exclusion could have been
mediated by the interviewer during the face to face inter-
view. A cross-sectional design may also make it difficult
to establish the cause and the effect, i.e., for this study, the
vaccine acceptability versus the knowledge of the disease
and the vaccine acceptability versus the age group.
Moreover, it has to be remarked that our investigation
didn't concern economical aspects of vaccination strate-
gies. Therefore, the questionnaire do not comprise ques-
tions about willingness-to-pay of interviewed subjects.
Conclusions
In this study compliance versus vaccination results were
satisfactory and it is possible to assume that, with the
upcoming availability of a HZ vaccine in Italy, adults will
be the population favourably disposed towards in vacci-
nation. However, the reported compliance must be con-
sidered only as an estimate and should be verified by
larger public health interventions and broaden cost-effec-
tiveness analyses.
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